EcoR1 Capital

Founded 2012
Founders Oleg Nodelman

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 74
Average round size
info
The average size of a deal this fund participated in
$91M
Portfolio companies 57
Rounds per year 8.22
Lead investments 6
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.23
Exits 41
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Pharmaceutical
Summary

EcoR1 Capital appeared to be the VC, which was created in 2012. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the San Francisco.

We also calculated 2 valuable employees in our database.

The usual cause for the fund is to invest in rounds with 8-9 partakers. Despite the EcoR1 Capital, startups are often financed by ARCH Venture Partners, Third Rock Ventures, The Column Group. The meaningful sponsors for the fund in investment in the same round are Fidelity Management and Research Company, Cormorant Asset Management, Samsara BioCapital. In the next rounds fund is usually obtained by Polaris Partners, Fidelity Management and Research Company, Cormorant Asset Management.

Among the most popular portfolio startups of the fund, we may highlight Clementia Pharmaceuticals, Relay Therapeutics, Codiak Biosciences. Among the most popular fund investment industries, there are Genetics, Medical Device. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little.

The increased amount of exits for fund were in 2018. The fund is generally included in 2-6 deals every year. Speaking about the real fund results, this VC is 15 percentage points less often commits exit comparing to other organizations. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Deals in the range of 50 - 100 millions dollars are the general things for fund. This EcoR1 Capital works on 22 percentage points more the average amount of lead investments comparing to the other organizations.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Cyclerion Therapeutics

Biotechnology
Pharmaceutical
$18M04 Jun 2021 Cambridge, Massachusetts, United States

Ajax Therapeutics

Biotechnology
Life Science
Medical
$40M01 Jun 2021 Cambridge, Massachusetts, United States

NiKang Therapeutics

Biotechnology
Health Care
Medical
$200M26 May 2021 Wilmington, Delaware, United States

Corvus Pharmaceuticals

Biopharma
Biotechnology
Pharmaceutical
$10M05 May 2021 California, United States

Janux Therapeutics

Biotechnology
Health Diagnostics
Pharmaceutical
Therapeutics
$125M20 Apr 2021 La Jolla, California, United States

Tectonic Therapeutic

Biotechnology
$80M15 Apr 2021 Boston, Massachusetts, United States

Aktis Oncology

Biotechnology
Life Science
$72M18 Mar 2021 Boston, Massachusetts, United States

ElevateBio

Biotechnology
Genetics
Health Care
Therapeutics
$525M15 Mar 2021 Cambridge, Massachusetts, United States

Centessa Pharmaceuticals

Biotechnology
Pharmaceutical
$250M16 Feb 2021 Cambridge, Massachusetts, United States
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

Ajax Therapeutics Raises $40 Million Financing To Develop Novel Small Molecules Targeting Cytokine Signaling Pathways for Hematologic Malignancies

– Ajax Therapeutics, Inc. announced the completion of a $40m financing.
– The round was led by EcoR1 Capital LLC with participation from additional new investor, Boxer Capital, as well as co-founding investors Inning One Ventures and Schrödinger, Inc.
– Existing research collaboration partners, Memorial Sloan Kettering Cancer Center (MSK) and NYU Langone Health, also participated in the financing.
– Concurrent with the financing, Scott Platshon, Partner of EcoR1 Capital, will join the Ajax Board of Directors.
– Proceeds from the financing will support the advancement of Ajax’ lead drug development programs targeting hematologic malignancies.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent EcoR1 Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: